Payload Information

Payload ID

STING agonist

STING agonist

Click to Show/Hide

Stimulator of interferon genes protein (STING1)

Target Info

General Information of This Payload

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

XMT-2056 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligible participants have HER2-positive recurrent/metastatic solid tumors with progressive disease, ECOG 0-1, and measurable lesions (RECIST 1.1). Key exclusions: recent immunosuppressive therapy (>10mg/day prednisone), prior STING-targeting treatment, active malignancy within 2 years (except low-risk cases), or untreated CNS metastases (stable/treated cases allowed with criteria). Click to Show/Hide
Administration Dosage	XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
*Related Clinical Trial*
NCT Number	NCT05514717	Phase Status	PHASE1
Clinical Description	A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2
Primary Endpoint	Safety and primary objectives focus on evaluating dose-limiting toxicities (DLTs), determining the maximum tolerated dose (MTD), and assessing adverse events over 15 months (Dose Escalation) and up to 3 years (Dose Expansion). The Objective Response Rate (ORR) is measured per RECIST 1.1 for confirmed responses.
Other Endpoint	Secondary outcomes include ORR, duration of response (DOR), disease control rate (DCR), and comprehensive pharmacokinetic assessments (Tmax, Cmax, AUC, clearance, half-life, volume of distribution, Ctrough) over 3 years. Immunogenicity is evaluated by measuring antidrug/neutralizing antibodies (ADA/NAb).

References

Ref 1	A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2